Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' obesity strategy
The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.
The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly. This story matters for Finance & Markets readers tracking currency. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. CurrencyNews curates and briefs the finance & markets stories that matter. Our editorial policy →